Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Taicang's Connect Biopharma Files for $100 Million NASDAQ IPO

publication date: Mar 5, 2021

Connect Biopharma of Taicang has filed for a NASDAQ IPO that could raise $100 million to support its clinical-stage portfolio of therapies for T cell-driven inflammatory diseases. Connect's lead candidate, CBP-201, is an antibody that targets interleukin-4 receptor alpha for inflammatory diseases such as atopic dermatitis and asthma. The company expects to report data from a Phase IIb trial in the 2H21. Connect says it uses functional cellular assays to conduct primary drug screens instead of high-throughput biochemical assays, resulting in differentiated products. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021